Glaxo to Manufacture Novavax Covid Shot Securing U.K. Supply

GlaxoSmithKline Plc is set to manufacture as many as 60 million U.K. doses of a Covid-19 vaccine from Novavax Inc. as the government looks to shore up supplies amid tensions with the European Union.

The British pharmaceutical company will provide the fill-finish capacity -- putting the vaccine into vials and packaging -- for the Novavax shot at its Barnard Castle site in Durham, England, Glaxo said in a statement Monday. Novavax is expected to apply for U.K. approval of its vaccine in the second quarter, with production at the Glaxo plant starting as early as May.

The drug substance for ...